Results 1 to 10 of about 10,162 (193)

Vitamin D supplementation for improving bone mineral density in children

The Cochrane Library
Tania Winzenberg, Graeme Jones, Kelly A Shaw   +2 more
exaly  

Diabetes, bone and glucose-lowering agents: clinical outcomes

Diabetologia, 2017
Ann Schwartz
exaly  

A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model

Bone, 1997
Jesper Skovhus Thomsen, Li Mosekilde, J S Thomsen   +2 more
exaly  

Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis

The Cochrane Library
Ina Monsef, Moritz Ernst, Nicole Skoetz   +2 more
exaly  

Seizures Associated With Bone Density Conservation Agents [PDF]

Journal of Pharmacy Technology, 2022
Objective The purpose of this review is to discuss the existing literature regarding patients who have experienced seizures after administration of a bone density conservation agent (BDCA). Data Sources A comprehensive literature ...
Kuan Sturgill, Justin P. Reinert
europepmc   +5 more sources

Therapeutic Drug Review on Romosozumab: The First Sclerostin Inhibitor [PDF]

Journal of Clinical and Diagnostic Research, 2022
Osteoporosis is a progressive skeletal disorder which is characterised by low bone mass, normal mineralisation and abnormal bone microarchitecture. This disruption of bone microarchitecture causes subsequent increase in bone fragility and raises risk of ...
Vijay Kumar Jain, Karthikeyan P Iyengar, Arvind Nune, Gaurav Kumar Upadhyaya   +3 more
doaj   +1 more source

When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

Frontiers in Endocrinology, 2021
Glucocorticoid-induced osteoporosis (GIOP) leads to fractures in up to 40% of patients with chronic glucocorticoid (GC) therapy when left untreated. GCs rapidly increase fracture risk, and thus many patients with anticipated chronic GC exposures should ...
Kaleen N. Hayes, Ulrike Baschant, Barbara Hauser, Barbara Hauser, Andrea M. Burden, Elizabeth M. Winter   +5 more
doaj   +1 more source

Denosumab treatment for osteopenia or osteoporosis in heart transplant recipients: Effects and safety

Transplantation Reports, 2022
Background: Osteoporosis is a prevalent complication in heart transplant population. Denosumab is a monoclonal antibody that inhibits bone resorption approved for the treatment of corticosteroid-induced osteoporosis and potentially useful in heart ...
Juan C. Uzquiano, Ana Alonso Méndez, Álvaro Juano Bielsa, María Dolores García-Cosío Carmena, Juan F. Delgado Jiménez, Paz Sanz-Ayán   +5 more
doaj   +1 more source

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Journal of Bone Oncology, 2022
Background: Giant-cell tumor of bone (GCTB) is a relatively benign, but locally aggressive osteoclastogenic stromal tumour of the bone. Although denosumab has been approved as an monoclonal antibody against RANK ligand for the treatment of GCTB, few ...
Jiaji Yue, Wei Sun, Shenglong Li
doaj   +1 more source

Dental Evaluation Prior to Cancer Therapy

Frontiers in Oral Health, 2022
A comprehensive oral examination and dental care prior to the start of cancer therapy is the standard of care in many cancer centers. This is because good oral health will likely minimize the undesirable complications such as opportunistic infections ...
Chee Weng Yong, Andrew Robinson, Catherine Hong   +2 more
doaj   +1 more source